C.R. Bard, Inc. (NYSE:BCR) Vice Chairman John H. Weiland sold 14,091 shares of C.R. Bard stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $240.49, for a total value of $3,388,744.59. Following the completion of the transaction, the insider now owns 68,978 shares in the company, valued at $16,588,519.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

C.R. Bard, Inc. (NYSE:BCR) opened at 241.79 on Friday. The stock has a market cap of $17.42 billion, a P/E ratio of 34.39 and a beta of 0.63. The stock’s 50 day moving average price is $234.21 and its 200-day moving average price is $222.72. C.R. Bard, Inc. has a one year low of $185.72 and a one year high of $242.50.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Thursday, January 26th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.74 by $0.03. C.R. Bard had a return on equity of 48.48% and a net margin of 14.31%. The firm had revenue of $967.10 million for the quarter, compared to the consensus estimate of $956.12 million. During the same quarter in the prior year, the business earned $2.43 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. On average, analysts predict that C.R. Bard, Inc. will post $11.64 earnings per share for the current year.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 3rd. Shareholders of record on Monday, January 23rd were issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend was Thursday, January 19th. C.R. Bard’s dividend payout ratio is 14.77%.

“John H. Weiland Sells 14,091 Shares of C.R. Bard, Inc. (BCR) Stock” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/02/17/john-h-weiland-sells-14091-shares-of-c-r-bard-inc-bcr-stock.html.

A number of brokerages recently issued reports on BCR. Barclays PLC restated a “hold” rating and issued a $245.00 target price on shares of C.R. Bard in a report on Sunday, January 29th. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $267.00 target price on the stock in a report on Tuesday, January 31st. Raymond James Financial, Inc. upgraded C.R. Bard from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $250.00 to $265.00 in a report on Thursday, January 5th. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a report on Friday, January 27th. Finally, JMP Securities lifted their target price on C.R. Bard from $240.00 to $255.00 in a report on Friday, January 27th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $244.14.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. IFM Investors Pty Ltd bought a new position in C.R. Bard during the fourth quarter worth $240,000. CAMG Solamere Management LLC bought a new position in C.R. Bard during the fourth quarter worth $739,000. Boothbay Fund Management LLC bought a new position in C.R. Bard during the fourth quarter worth $231,000. Cigna Investments Inc. New bought a new position in C.R. Bard during the fourth quarter worth $625,000. Finally, Guggenheim Capital LLC increased its position in C.R. Bard by 7.3% in the fourth quarter. Guggenheim Capital LLC now owns 208,578 shares of the company’s stock worth $46,858,000 after buying an additional 14,265 shares during the period. 86.89% of the stock is currently owned by hedge funds and other institutional investors.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.